FDA Clearance Tracker · P110022-S022
Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgM
Last checked: Nov 20, 2026Latest source record: Dec 21, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Dec 21, 2017
Approved
Time to decision
168 days
Received Jul 6, 2017. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class II
The decision
- FDA number
- P110022-S022
- Device name
- Elecsys Anti-HBc IgM and PreciControl Anti-HBc IgM
- Applicant
- Roche Diagnostics Corp.
- Applicant location
- Indianapolis, IN
- Received
- Jul 6, 2017
- Decided
- Dec 21, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P110022
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for migration of the Elecsys Anti-HBc IgM Immunoassay and Elecsys PreciControl Anti-HBc IgM to the cobas e 801 immunoassay analyzer.
Source documents
Other decisions for Roche Diagnostics Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.